Pleiotropic effects of omega-3 fatty acids

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 1, 2012, Pages 40-46

  Papazafiropoulou, Athanasia K ^a   Kardara, Marina S ^a   Pappas, Stavros I ^a  

^a GENERAL HOSPITAL OF NIKEA   (Greece)

Author keywords

Arrhythmia; Blood pressure; Cancer; Dementia; Omega 3 fatty acids; Pleiotropic effects; Triglycerides

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLEEDING; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; BREAST CANCER; COLORECTAL CANCER; DEPRESSION; DYSLEXIA; HEART ARRHYTHMIA; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MERCURIALISM; NONHUMAN; PERSONALITY DISORDER; PLEIOTROPY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; HYPOLIPIDEMIC AGENTS; LEGISLATION, DRUG; PATENTS AS TOPIC;

EID: 84856551622     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412799015254     Document Type: Review

References (134)

1. Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000; 71: 179-88.
2. Hussein N, Ah-Sing E, Wilkinson P, Leach C, Griffin BA, Millward DJ. Long-chain conversion of [13C] linoleic acid and alphalinolenic acid in response to marked changes in their dietary intake in men. J Lipid Res 2005; 46: 269-80.
3. Sprecher H. The roles of anabolic and catabolic reactions in the synthesis and recycling of polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 79-83.
4. Burdge G. Alpha-linolenic acid metabolism in men and women: Nutritional and biological implications. Curr Opin Clin Nutr Metab Care 2004; 7: 137-44.
5. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 2002; 88: 411-20.
6. Bolton-Smith C, Woodward M, Tavendale R. Evidence for agerelated differences in the fatty acid composition of human adipose tissue, independent of diet. Eur J Clin Nutr 1997; 51: 619-24.
7. Sands SA, Reid KJ, Windsor SL, Harris WS. The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 2005; 40: 343-7.
8. Faas FH, Dang AQ, Kemp K, Norman J, Carter WJ. Red blood cell and plasma fatty acid composition in diabetes mellitus. Metabolism 1988; 37: 711-3.
9. Rao S, Erasmus RT. Pilot study on plasma fatty acids in poorly controlled non insulin dependent diabetic Melanesians. East Afr Med J 1996; 73: 816-8.
10. van Doormaal JJ, Muskiet FA, van Ballegooie E, Sluiter WJ, Doorenbos H. The plasma and erythrocyte fatty acid composition of poorly controlled, insulin-dependent (type I) diabetic patients and the effect of improved metabolic control. Clin Chim Acta 1984; 144: 203-12.
11. Stark KD, Mulvad G, Pedersen HS, Park EJ, Dewailly E, Holub BJ. Fatty acid compositions of serum phospholipids of postmenopausal women: A comparison between Greenland Inuit and Canadians before and after supplementation with fish oil. Nutrition 2002; 18: 627-30.
12. Stark KD, Beblo S, Murthy M, Whitty JE, Buda-Abela M, Janisse J, et al. Alcohol consumption in pregnant, black women is associated with decreased plasma and erythrocyte docosahexaenoic acid. Alcohol Clin Exp Res 2005; 29: 130-40.
13. Institute of Medicine of the National Academies. Dietary reference intakes for energy, carbohydrates, fiber, fat, fatty acids, cholesterol, protein, and amino acids, Washington, DC, National Academy of Sciences 2002; 364-74.
14. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-57.
15. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002; 106:3143-421.
16. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997; 4: 385-91.
17. Harris W. n-3 Fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr 1997; 65: 1645S-54S.
18. Lovegrove JA, Lovegrove SS, Lesauvage SV, Brady LM, Saini N, Minihane AM, et al. Moderate fish-oil supplementation reverses low-platelet, long-chain n-3 polyunsaturated fatty acid status and reduces plasma triacylglycerol concentrations in British Indo- Asians. Am J Clin Nutr 2004; 79: 974-82.
19. Buckley R, Shewring B, Turner R, Yaqoob P, Minihane A. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr 2004; 92: 477-83.
20. Dyerberg J, Eskesen DC, Andersen PW, Astrup A, Buemann B, Christensen JH, et al. Effects of trans-and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males: An 8 weeks dietary intervention study. Eur J Clin Nutr 2004; 58: 1062-70.
21. Svensson M, Christensen J, Solling J, Schmidt E. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. Am J Kidney Dis 2004; 44: 77-83.
22. Lindman A, Pedersen J, Hjerkinn E, Arnesen H, Veierod M, Ellingsen I, et al. The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thromb Haemost 2004; 91: 1097-104.
23. Tholstrup T, Hellgren LI, Petersen M, Basu S, Straarup EM, Schnohr P, et al. A solid dietary fat containing fish oil redistributes lipoprotein subclasses without increasing oxidative stress in men. J Nutr 2004; 134: 1051-7.
24. Theobald HE, Chowienczyk PJ, Whittall R, Humphries SE, Sanders TA. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr 2004; 79: 558-63.
25. Calabresi L, Villa B, Canavesi M, Sirtori C, James R, Bernini F, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 2004; 53:153-8.
26. Phillipson B, Rothrock D, Connor W, Harris W, Illingsworth D. Reduction of plasma lipids, lipoproteins and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985; 312:1210-6.
27. Nettleton JA, Katz R. N-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review. J Am Diet Assoc 2005; 105: 428-40.
28. Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, et al. For the Tufts-New England Medical Center Evidence- Based Practice Center, Boston, MA. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease: Summary, Evidence Report/Technology Assessment No. 93. Rockville, MD: Agency for Healthcare Research and Quality; March 2004. AHRQ Publication No. 04-E010-2.
29. Harris W. Nonpharmacologic treatment of hypertriglyceridemia: Focus on fish oils. Clin Cardiol 1999; 22 (suppl II):40 -3.
30. Appel LJ, Miller ER, Seidler AJ, Whelton PK. Does supplementation of diet with Bfish oil reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 1993; 153: 1429-38.
31. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88: 523-33.
32. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000; 102: 1264-9.
33. Engler MM, Engler MB, Goodfriend TL, Ball DL, Yu Z, Su P, et al. Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR. Exp Biol Med 1999; 221: 32-8.
34. Engler MM, Engler MB, Kroetz DL, Boswell KD, Neeley E, Krassner SM. The effects of a diet rich in docosahexaenoic acid on organ and vascular fatty acid composition in spontaneously hypertensive rats. Prostaglandins Leukot Essent Fat Acids 1999; 61: 289-95.
35. Engler MM, Engler MB, Pierson DM, Moleni LB, Molteni A. Effects of docosahexaenoic acid on vascular pathologyand reactivity in hypertension. Exp Biol Med 2003; 228: 229-307.
36. Engler MB, Engler MM. Docosahexaenoic acid-induced vasorelaxation in hypertensive rats: Mechanisms of action. Biol Res Nurs 2000; 2: 85-95.
37. Engler MB, Engler MM, Browne A, Sun Y-P, Sievers R. Mechanisms of vasorelaxation induced by eicosapentaenoic acid (20:5nj3) in WKY rat aorta. Br J Pharmacol 2000; 131: 1793-9.
38. Engler MB, Ma Y-H, Engler MM. Calcium-mediatedmechanisms of eicosapentaenoic acid-induced relaxation in hypertensive rat aorta. Am J Hypertens 1999; 12: 1225-35.
39. Engler MB. Effects of omega-3, omega-6 and omega-9 fatty acids on vascular smooth muscle tone. Eur J Pharmacol 1992; 215: 325-8.
40. Engler MB. Effect of omega-3 fatty acids, docosahexaenoic and eicosapentaenoic, on norepinephrine-induced contractions. Can J Physiol Pharmacol 1992; 70: 675-9.
41. Engler MB, Engler MM, Ursell PC. Vasorelaxant properties of n-3 polyunsaturated fatty acids in aorta from spontaneously hypertensive and normotensive rats. J Cardiovasc Risk 1994; 1: 75-80.
42. Engler MB, Engler MM, Mayes M, Ursell PC. Effects of the omega-3 fatty acids on vascular tone in hypercholesterolemia and balloon arterial injury. Asia Pac Heart J 1999; 8: 27-35.
43. Engler MB, Engler MM. Influence of aging on the relaxant responses to <-3 fatty acids in Fischer 344 rat aorta. Gerontology 1996; 42: 25-35.
44. Chin JP, Dart AM. Therapeutic restoration of endothelial function in hypercholesterolemic subjects: Effect of fish oils. Clin Exp Pharmacol Physiol 1994; 21: 749-55.
45. Goode GK, Garcia S, Heagerty AM. Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. Circulation 1997; 96: 2802-7.
46. Goodfellow J, Bellamy MF, Ramsay MW, Jones CJ, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000; 35: 265-70.
47. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
48. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
49. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-9.
50. Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) trial. Circulation 2003; 108: 1059-63.
51. Engler MM, Engler MB, Malloy M, Chiu E, Besio D, Paul S, et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: Results from the EARLY study. Int J Clin Pharmacol Ther 2004; 42: 672-9.
52. Järvisalo MJ, Rönnemaa T, Volanen I, Kaitosaari T, Kallio K, Hartiala JJ, et al. Brachial artery dilation responses in healthy children and adolescents. Am J Physiol Heart Circ Physiol 2002; 282: 87-92.
53. Okuda Y, Kawashima K, Sawada T, Tsurumaru K, Asano M, Suzuki S, et al. Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Commun 1997; 232: 487-91.
54. Harris WS, Rambjor GS, Windor SL, Diederich D. nJ3 Fatty acids and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr 1997; 65: 459-64.
55. Kang JX, Leaf A. Prevention of fatal cardiac dysrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 2000; 71: 202-7.
56. McLennan PL, Abeywardena MY, Charnock JS. Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion. Am Heart J 1988; 116: 709-17.
57. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation 1999; 99: 2452-7.
58. Christensen JH, Ejlersen E, Jessen T. nJ3 fatty acids and ventricular extra systoles in patients with ventricular tachydysrhythmias. Nutr Res 1995; 15: 1-8.
59. Sellmayer A, Witzgall H, Lorenz R, Weber PC. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol 1995; 76: 974.
60. Singer P, Wirth M. Can nj3 PuFA reduce cardiac dysrhythmias? Results of a clinical trial. Prostaglandins Leukot Essent Fat Acids 2004; 71: 153-9.
61. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110: 368-73.
62. Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997;17: 279-86.
63. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 1997; 65: 1687-98.
64. Libby P. Atherosclerosis: The new view. Sci Am 2002; 286: 46-55.
65. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
66. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 2002; 8: 1249-56.
67. Collie Duguid ES, Wahle KW. Inhibitory effect of fish oil nj3 polyunsaturated fatty acids on the expression of endothelial cell adhesion molecules. Biochem Biophys Res Commun 1996; 220: 969-74.
68. DeCaterina R, Barnini W, Carluccio MA, Liao JK, Libby P. Structural requirements for inhibition of cytokineinduced endothelial activation by unsaturated fatty acids. J Lipid Res 1998; 39: 1062-70.
69. DeCaterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000; 71: 213-23.
70. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 2003; 361: 477-85.
71. Cohen LA. Lipid in cancer: An introduction. J Am Oil Chem Soc 1992; 27: 791-2.
72. Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: Modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res 1997; 57: 3465-70.
73. Kimura Y, Kono S, Toyomura K, Nagano J, Mizoue T, Moore MA, et al. Meat, fish and fat intake in relation to subsite-specific risk colorectal cancer: The Fukuoka Colorectal Cancer Study. Cancer Sci 2007; 98: 590-7.
74. Theodoratou E, McNeill G, Cetnarskyi R, Farrington SM, Tenesa A, Barnetson R, et al. Dietary fatty acids and colorectal cancer: A case-control study. Am J Epidemiol 2007; 166: 181-95.
75. Kuriki K, Wakai K, Hirose K, Matsuo K, Ito H, Suzuki T, et al. Risk of colorectal cancer is linked to erythrocyte compositions of fatty acids as biomarkers for dietary intakes of fish, fat, and fatty acids. Cancer Epidemiol Biomarkers Prev 2006; 15: 1791-8.
76. Kuriki K, Hirose K, Wakai K, Ito H, Suzuki T, Hiraki A, et al. Breast cancer risk and erythro-cyte compositions of n-3 highly unsaturated fatty acids in Japanese. Int J Cancer 2007; 121: 377-85.
77. Giovunncci F, Willett WC. Dietary factors and risk of colon cancer. Ann Med 1994; 26: 443-52.
78. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA 1995; 92: 5258-65.
79. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long chain n-3 fatty acids for the prevention of cancer: A review of potential mechanisms. Am J Clin Nut 2004; 79: 935-45.
80. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, Reber HA, et al. Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas 2008; 36: 353-62.
81. Escrich E, Solanas M, Moral R, Costa I, Grau L. Are the olive oil and other dietary lipids related to cancer? Experimental evidence. Clin Transl Oncol 2006; 8: 868-83.
82. Dommels YE, Heemskerk S, van den Berg H, Alink GM, van Bladeren PJ, van Ommen B. Effects of high fat fish oil and high fat corn oil diets on initiation of AOM-induced colonic aberrant crypt foci in male F344 rats. Food Chem Toxicol 2003; 41: 1739-47.
83. Foley JM, Stark KD, Zajchowski S, Meckling KA. Fatty acids and exercise affect glucose transport but not tumour growth in F-344 rats. Can J Appl Physiol 2004; 29: 604-22.
84. Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Whelan J. Highly unsaturated (n-3) fatty acids, but not alpha-linolenic, conjugated linoleic or gamma-linolenic acids, reduce tumorigenesis in Apc(Min/_) mice. J Nutr 2000; 130: 2434-43.
85. Yuri T, Danbara N, Tsujita-Kyutoku M, Fukunaga K, Takada H, Inoue Y, et al. Dietary docosahexaenoic acid suppresses N-methyl- N-nitrosourea-induced mammary carcinogenesis in rats more effectively than eicosapentaenoic acid. Nutr Cancer 2003; 45: 211-7.
86. Uauy R, Dangour AD. Nutrition in brain development and aging: role of essential fatty acids. Nutr Rev 2006; 64(suppl): 24-33.
87. Mitchell DC, Niu SL, Litman BJ. DHA-rich phospholipids optimize G-protein-coupled signaling. J Pediatr 2003; 143(suppl): 80-6.
88. Wood JN. Essential fatty acids and their metabolites in signal transduction. Biochem Soc Trans 1990; 18: 785-6.
89. Stubbs CD, Smith AD. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 1984; 779: 89-137.
90. Murphy MG. Dietary fatty acids and membrane protein function. J Nutr Biochem 1990; 1: 68-79.
91. du Bois TM, Deng C, Bell W, Huang XF. Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain. Neuroscience 2006; 139: 1397-403.
92. Fenton WS, Hibblen J, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 47: 8-21.
93. Bennett CN, Horrobin DF. Gene targets related to phospholipids and fatty acid metabolism in schizophrenia and other psychiatric disorders: An update. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 47-59.
94. Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry. 2001; 6: 246-8.
95. Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005; 65: 1051-9.
96. Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II: Fatty acid composition. Schizophr Res 1994; 13: 217-26.
97. Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P. Fish consumption and depression: The Northern Finland 1966 birth cohort study. J Affect Disord 2004; 82: 447-52.
98. Edwards R, Peet M, Shav J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998; 48: 149-55.
99. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006; 18: 155-72.
100. Haag M. Essential fatty acids and the brain. Can J Psychiatry 2003; 48: 195-203.
101. Colter AL, Cutler C, Meckling KA. Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: A case-control study. Nutr J 2008; 7: 8.
102. Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003; 38: 1007-21.
103. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention deficit/hyperactivity disorder-A placebo-controlled double-blind study. Eur J Clin Nutr 2004; 58: 467-73.
104. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attentiondeficit/ hyperactivity disorder. J Pediatr 2001; 139: 189-96.
105. Kamphuis MH, Geerlings MI, Tijhuis MAR, Kalmijn S, Grobbee DE, Kromhout D. Depression and cardiovascular mortality: A role for n-3 fatty acids? Am J Clin Nut 2006; 84: 1513-7.
106. Su K-P, Huang S-Y, Chiu C-C, Shen WW. Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo controlled trial. Eur Neuropsychopharmacol 2003; 13: 267-71.
107. Hallahan B, Hibbeln JR, Davis JM, Garland MR. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Singlecentre double-blind randomised controlled trial. Br J Psychiatry 2007; 190: 118-22.
108. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega- 3treatment of childhood depression: A controlled, double-blind pilot study. Am J Psychiatry 2006; 163: 1098-100.
109. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, et al. Double-blind, randomized, placebocontrolled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006; 60: 1020-22.
110. Rees AM, Austin MP, Parker GB. Omega-3 fatty acids as treatment for perinatal depression: Randomized double-blind placebocontrolled trial. Aust N Z Psychiatry 2008; 42: 199-205.
111. Freeman MP, Davis M, Sinha P, Wisnar KL, Hibbeln JR, Gelenberg AJ. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: A randomized placebo-controlled study. J Affect Disord 2008; 110: 142-8.
112. Ott A, Breteler MMB, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, et al. Prevalence of Alzheimer's disease and vascular dementia: Association with education. The Rotterdam study. BMJ 1995; 310: 970-3.
113. Kinsella K, Velkoff VA. An Aging World: 2001. Washington, DC: US Government Printing Office; 2001. US Census Bureau Series P95/ 01-1.
114. Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: A review of clinical and epidemiological studies. J Nutr Health Aging 2000; 4: 202-7.
115. Honig LS. Inflammation in neurodegenerative disease. Good, bad, or irrelevant? Arch Neurol 2000; 57: 786-8.
116. Kalmijn S, van Boxtel MP, Ocke M, Verschuren VM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004; 62: 275-80.
117. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham heart study. Arch Neurol 2006; 63: 1545-50.
118. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman JC, et al. Diet and risk of dementia: Does fat matter?: The Rotterdam study. Neurology 2002; 59: 1915-21.
119. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, et al. Ω-3 Fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD Study. Arch Neurol 2006; 63: 1402-8.
120. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006; 56: 159-64.
121. Boston PF, Bennett A, Horrobin DF, Bennett CN. Ethyl-EPA in Alzheimer's disease-a pilot study. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 341-6.
122. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 2006; 296: 1885-99.
123. Innis SM, Palaty J, Vaghri Z, Lockitch G. Increased levels of mercury associated with high fish intakes among children from Vancouver, Canada. J Pediatr 2006; 148: 759-63.
124. What You Need to Know About Mercury in Fish and Shellfish. Washington,DC: Food and Drug Administration, Environmental Protection Agency; 2004 Publication No. EPA-823-R-04-005.
125. Foran SE, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: Is fish oil healthier than fish? Arch Pathol Lab Med 2003; 127: 1603-5.
126. Helland IB, Saugsted OD, Smith L, Saarem K, Solvoll K, Ganes T, et al. Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. Pediatrics 2001; 108: E82.
127. Consumer advisory: An important message for pregnant women and women of childbearing age who may become pregnant about the risks of mercury in fish. March 2001. US Food and Drug Administration Center for Food Safety and Applied Nutrition Web site. http://vm.cfsan.fda.gov/_dms/admehg.html. (Accessed May 7, 2008).
128. Harris WS. Expert opinion: Omega-3 fatty acids and bleeding- Cause for concern? Am J Cardiol 2007;99:44C-6C.
129. Coy, J., Otzberg, D. Beverage. CA2627038C (2011).
130. Renshaw, P. F., Carlezon W. A., Cohen, B. M. Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids. US20100197628 (2010).
131. Goodman, D.W., Hanley, M.R., Bursten, S.L., Serhan, C.N. Analogues of lipid mediators derived from ω-3 PUFAs and methods of use. US7378444 (2008) & US7595341 (2009).
132. Shibuya, H., Komae, J.P. Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events. US7619002 (2009).
133. Granata, F., Pamparana, F., Stragliotto, E. Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy. US7439267 (2008).
134. De Meester, F. Food comprising polyunsaturated fatty acids for the prevention of chronic diseases. EP1961311 (2008).